The link for Ridgewood Health Department vaccine appointments has been temporarily removed due to lack of vaccine.


The Village of Ridgewood will begin scheduling COVID Vaccine appointments starting on Monday April 26th, 2021 at 9:30am if the vaccine shipment allows.

Please keep in mind that Ridgewood is not guaranteed to receive doses of the COVID-19 vaccine.  Once you complete and submit the COVID Vaccine Registration form, you will receive a confirmation email from with your registration submission information. will email you with an appointment time and date if an appointment is available. 


Millions of people have safely received a COVID-19 vaccine, Over 211 million doses of COVID-19 vaccine were administered in the United States from December 14, 2020, through April 19, 2021.

COVID-19 vaccines are safe and effective. COVID-19 vaccines were evaluated in tens of thousands of participants in clinical trials. The vaccines met FDA’s rigorous scientific standards for safety, effectiveness, and manufacturing quality needed to support emergency use authorization (EUA).

Millions of people in the United States have received COVID-19 vaccines, and these vaccines will undergo the most intensive safety monitoring in U.S. history. This monitoring includes using both established and new safety monitoring systems to make sure that COVID-19 vaccines are safe (CDC, 2021).


See the following links for additional information regarding Vaccine appointments:

Please click on to find current available appointments in New Jersey.

To register on New Jersey’s Vaccine Scheduling system please visit      

Find local Vaccine Centers near you clicking on the following link:


If you need assistance or are Homebound and seeking a COVID vaccine please call 201 670-5500; 244 or email


Thank you,

- Village of Ridgewood Health Department

  • Hits: 93

Please note the following statement from Commissioner Persichilli, along with messaging that was sent to all PODs.


Statement from New Jersey Health Commissioner Judith Persichilli

Out of an abundance of caution and following the guidance of the U.S. Centers for Disease Control and Prevention (CDC) and the U. S. Food and Drug Administration (FDA), the New Jersey Department of Health this morning paused the administration of the Johnson & Johnson (Janssen) vaccine across all vaccination sites in the state.

The CDC and the FDA are reviewing the data involving six reported cases—among nearly 7 million doses administered in the U.S.—in women between the ages of 18 and 48 who received the J&J vaccine. Symptoms occurred 6 to 13 days after vaccination. In these cases, a type of blood clot called cerebral venous sinus thrombosis was seen in combination with low levels of blood platelets. Both the CDC and FDA have said that these adverse events are extremely rare. According to the FDA and CDC, individuals who have received the vaccine and develop abdominal pain, leg pain, shortness of breath, severe headache or other unusual symptoms within three weeks after vaccination should contact their health care provider.

All New Jersey vaccination sites have been told to cancel or put on hold appointments for the J&J vaccine until further notice. For individuals scheduled to receive the J&J vaccine, the Department will work with all vaccination sites to make arrangements for the administration of an alternative two-dose vaccine. We will work with all sites, as needed, to reschedule vaccination appointments.

The Department will await further guidance from the federal government. The federal Advisory Committee on Immunization Practices (ACIP) is scheduled to hold an emergency meeting tomorrow to discuss these adverse events and make recommendations to the CDC on how to proceed.






Alert: Joint CDC and FDA Statement on J and J COVID-19 Vaccination


The NJ Department of Health directs all PODs to pause J and J vaccinations.  Cancel all J and J vaccination clinics, including today and moving forward, until further guidance is released.


The New Jersey Department of Health, Vaccine Preventable Disease Program recommends that the Johnson and Johnson vaccine be maintained within your vaccine storage unit at the appropriate refrigerator temperature of 2 – 8 degrees C (36 – 46 degrees F).  Please segregate the Johnson and Johnson vaccine in your storage unit with a label that says “DO NOT USE” pending further guidance.  



Joint CDC and FDA Statement on Johnson & Johnson COVID-19 Vaccine

The following statement is attributed to Dr. Anne Schuchat, Principal Deputy Director of the CDC and Dr. Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research



As of April 12, more than 6.8 million doses of the Johnson & Johnson (Janssen ) vaccine have been administered in the U.S. CDC and FDA are reviewing data involving six reported U.S. cases of a rare and severe type of blood clot in individuals after receiving the J&J vaccine. In these cases, a type of blood clot called cerebral venous sinus thrombosis (CVST) was seen in combination with low levels of blood platelets (thrombocytopenia). All six cases occurred among women between the ages of 18 and 48, and symptoms occurred 6 to 13 days after vaccination. Treatment of this specific type of blood clot is different from the treatment that might typically be administered. Usually, an anticoagulant drug called heparin is used to treat blood clots. In this setting, administration of heparin may be dangerous, and alternative treatments need to be given.


CDC will convene a meeting of the Advisory Committee on Immunization Practices (ACIP) on Wednesday to further review these cases and assess their potential significance. FDA will review that analysis as it also investigates these cases. Until that process is complete, we are recommending a pause in the use of this vaccine out of an abundance of caution. This is important, in part, to ensure that the health care provider community is aware of the potential for these adverse events and can plan for proper recognition and management due to the unique treatment required with this type of blood clot.


Right now, these adverse events appear to be extremely rare. COVID-19 vaccine safety is a top priority for the federal government, and we take all reports of health problems following COVID-19 vaccination very seriously. People who have received the J&J vaccine who develop severe headache, abdominal pain, leg pain, or shortness of breath within three weeks after vaccination should contact their health care provider. Health care providers are asked to report adverse events to the Vaccine Adverse Event Reporting System at


CDC and FDA will provide additional information and answer questions later today at a media briefing. A recording of that media call will be available on the FDA’s YouTube channel.





CDC works 24/7 protecting America’s health, safety and security. Whether diseases start at home or abroad, are curable or preventable, chronic or acute, or from human activity or deliberate attack, CDC responds to America’s most pressing health threats. CDC is headquartered in Atlanta and has experts located throughout the United States and the world.



Confidentiality Notice: This e-mail, including any attachments, may include advisory, consultative and/or deliberative material and, as such, would be privileged and/or confidential and not a public document. Any information in this e-mail identifying a client of the Department of Health or including protected health information is confidential. If you received this e-mail in error, you are not authorized to review, transmit, convert to hard copy, copy, or in any way further use or disseminate this e-mail or any attachments to it. You must immediately notify the sender and delete this message. If the email you received in error contained client or protected health information, you must also notify the Data Privacy Officer immediately at and confirm in writing that you deleted the email(s)/attachment(s) and that you did not/will not further use or disclose the information contained in the email.

  • Hits: 101



Ridgewood, NJ:  Free tree seedlings will be available to Ridgewood residents on Saturday, May 1 as part of the NJ Forest Service's New Jersey Tree Recovery Campaign.

In celebration of Arbor Day and in an ongoing effort to re-tree and sustain Ridgewood trees, the Ridgewood Department of Parks and Recreation Shade Tree Division and the Ridgewood Shade Tree Commission are supporting this distribution.

From 10 am to 12 noon residents will be able to pick up seedlings at the Graydon Parking Lot.  Registration is required as supply is limited and distribution will be contactless.  Information on proper planting and care will be provided.  Residents should plant the seedlings with two days after pick-up in order to prevent the roots from drying out.

To register for seedlings and further information, contact Carolyn Jacoby,

  • Hits: 268

The Village of Ridgewood is in search of volunteers to serve on the Ridgewood Historic Preservation Commission as Class A, Class B, and Class C members:

  • Class A members are knowledgeable in building design and construction or architectural history.


  • Class B members are  knowledgeable about, or have a demonstrated interest in, local Ridgewood history.


  • Class C members are residents of Ridgewood holding no other office, position, or employment except for membership on the Planning Board or Zoning Board of Adjustment.


  • Qualified Class A and B members may reside outside of Ridgewood.


  • HPC duties are listed below – HPC meets monthly on a Thursday at 7:30pm – meetings may be added on an as-needed basis.


Please complete the Ridgewood Citizen Volunteer Leadership Form and submit w/cover letter, resume and/or bio to (copy Mayor Knudsen no later than March 31, 2021 (subject line: HPC)

Responsibilities of the Ridgewood Historic Preservation Commission:


  1. To identify, record and maintain a system for survey and inventory of all buildings, sites, places, landmarks and structures of historical or architectural significance based on the Secretary of the Interior's Standards and Guidelines for Archaeology and Historic Preservation (Standards and Guidelines for Identification); and to aid the public in understanding their worth, methods of preservation, techniques of gathering documentation and related matters.


  1. To advise the Planning Board on the relationship of the Historic Preservation Plan       Element of the Master Plan to other Master Plan elements.


  1. To advise the Planning Board on the inclusion of historic sites and landmarks in the recommended Capital Improvement Program.


  1. To advise the Planning Board and Zoning Board of Adjustment on applications for development pursuant to N.J.S.A. 40:55D-110.


  1. Attend regular monthly meeting and additional meetings, as necessary.



  • Hits: 569


If you have any trouble with accessing information contained within this website, please contact Dylan Hansen - 201-670-5500 x276 or by email